BASTA trial: protocol for a randomised, double-blind, placebo-controlled, crossover trial investigating the effects of atorvastatin on bile acid diarrhoea
Abstract
Introduction: Bile acid diarrhoea (BAD) is a chronic disease with typical symptoms of daily watery stools with increased frequency and urgency. BAD arises due to pathologically high levels of bile acids in the colon, which may be due to impaired reabsorption or increased synthesis. Evidence indicates that atorvastatin administration suppresses bile acid synthesis in healthy individuals, likely due to reduced substrate availability. The Bile Acid diarrhoea STAtin Trial aims to investigate whether atorvastatin treatment reduces bile acid synthesis in patients with BAD and consequently alleviates BAD symptoms.
Methods and analysis: 20 adults with moderate-to-severe BAD, assessed by the gold standard diagnostic test 75selenium homotaurocholic acid test, will be randomised to begin with either placebo or atorvastatin 40 mg once daily for 2 weeks, followed by 80 mg once daily for another 2 weeks. After a 4-week washout period, participants will cross over to the alternate treatment. The primary endpoint is the relative difference between atorvastatin and placebo treatment in bile acid synthesis rate, measured by the validated biomarker 7alpha-hydroxy-4-cholesten-3-one (C4) and key secondary endpoints include mean differences in daily stool frequency.
Ethics and dissemination: The study is approved by the Danish Medicines Agency and the Regional Scientific Ethics Committee of the Capital Region of Denmark (2025-521 856-47-00) and registered with the Danish Data Protection Agency…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.